公开(公告)号：USRE39420E1

公开(公告)日：2006-12-05

申请号：US09678218

申请日：2000-09-29

申请人： Tomio Kimura ,  Yasuo Noguchi ,  Akira Nakao ,  Keisuke Suzuki ,  Shigeru Ushiyama ,  Akihiro Kawara ,  Masaaki Miyamoto

发明人： Tomio Kimura ,  Yasuo Noguchi ,  Akira Nakao ,  Keisuke Suzuki ,  Shigeru Ushiyama ,  Akihiro Kawara ,  Masaaki Miyamoto

IPC分类号： A61K31/40 ,  C07D207/333 ,  C07D207/335 ,  C07D207/337

CPC分类号： C07D207/333 ,  C07D207/335 ,  C07D207/337

摘要： Compounds of formula (I) and (II): [wherein R is hydrogen, halogen or alkyl; R1 is alkyl, amino or substituted amino; R2 is optionally substituted phenyl; R3 is hydrogen, halogen or optionally substituted alkyl; R4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl] have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

摘要翻译： 式（I）和（II）的化合物：[其中R是氢，卤素或烷基; R 1是烷基，氨基或取代的氨基; R 2是任选取代的苯基; R 3是氢，卤素或任选取代的烷基; R 4是氢，任选取代的烷基，环烷基，芳基或芳烷基]具有有价值的镇痛，抗炎，抗裂解和抗过敏活性，并且具有抑制白三烯生产的能力和 以抑制骨吸收。 它们相对没有通常由施用具有这些活性的化合物引起的副作用。

公开(公告)号：US07091352B2

公开(公告)日：2006-08-15

申请号：US10625024

申请日：2003-07-22

申请人： Tomio Kimura ,  Akira Nakao

发明人： Tomio Kimura ,  Akira Nakao

IPC分类号： C07D221/02

CPC分类号： C07D471/04 ,  C07D455/02 ,  C07D487/04

摘要： Compounds of the formula (I) below, or pharmacologically acceptable salts, esters or other derivatives thereof: wherein A is furan, thiophene, pyrazole, imidazole, isoxazole or isothiazole; R1 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; R2 is a substituted or unsubstituted heteroaryl; and R3 is a bicyclic amino group; provided that the substituents R1 and R2 are bonded to the two atoms of the cyclic group A which are adjacent to the atom of the cyclic group A to which the substituent R2 is bonded. The compounds inhibit the production of inflammatory cytokines.

摘要翻译： 式（I）的化合物或其药理学上可接受的盐，酯或其衍生物：其中A为呋喃，噻吩，吡唑，咪唑，异恶唑或异噻唑; R 1是取代或未取代的芳基或取代或未取代的杂芳基; R 2是取代或未取代的杂芳基; R 3是双环氨基; 条件是取代基R 1和R 2与键合在与环状基团A的原子相邻的环状基团A的两个原子上，取代基R ^{2 键合。 这些化合物抑制炎性细胞因子的产生。}

公开(公告)号：US06471946B1

公开(公告)日：2002-10-29

申请号：US09673618

申请日：2000-10-19

申请人： Tsutomu Takatsuka ,  Akira Nakao

发明人： Tsutomu Takatsuka ,  Akira Nakao

IPC分类号： A61K716

CPC分类号： A61Q11/00 ,  A61K8/21 ,  A61K8/27 ,  A61K8/60 ,  Y10S514/835 ,  Y10S514/901

摘要： Disclosed is an oral composition comprising palatinit. More particularly, disclosed is an oral composition comprising palatinit which exerts a synergistic effect when combined with a fluorine or zinc compound.

摘要翻译： 公开了包含palatinit的口服组合物。 更具体地，公开了包含与氟或锌化合物组合时发挥协同作用的palatinit的口服组合物。